Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Dupilumab on Exercise Capacity in Moderate-to-Severe Asthma
2019-002742-20Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in asthma comparing Dupilumab with Placebo (2 arms). Primary endpoint: Change from baseline to week 12 in constant work rate exercise endurance time. Started Apr 2020; status: completed.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on 2019-002742-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002742-20.